From a cancer therapeutics perspective, the promising tumor growth inhibition observed in our xenograft study support the evaluation of BOLD-100 in combination with novel ATR inhibitors or other inhibitors of the replication stress response (e.g., CHK1 inhibitors) in clinical trials for patients with metastatic BRAFMT colorectal cancer. This evidence concerns the gene CHEK1 and colorectal cancer.